BioSIM 抗人 Syndecan-1/CD138 抗体

产品核心信息总览

本产品为InvivoCrown供应的BioSIM 抗人 Syndecan-1/CD138 抗体（雷英妥昔单抗），属于生物类似药范畴，专为科研场景设计，具备明确的靶标特异性与应用适配性。

一、基础属性

• 英文全称：BioSIM anti-Human Syndecan-1/CD138 Antibody (Indatuximab Biosimilar), Research Grade
• 中文全称：BioSIM 抗人 Syndecan-1/CD138 抗体（雷英妥昔单抗），生物类似药，科研用途
• 供应商：InvivoCrown
• 产品货号：SIM0234-1mg
• 单支规格：1mg

二、生产工艺与背景

该抗体为雷英妥昔单抗的生物类似药，生产过程遵循严格质控标准：

• 全程在无动物成分的设施中生产，规避动物源污染物引入风险；
• 仅采用体外无蛋白细胞培养技术，保障批次间生产一致性；
• 经多步骤纯化工艺制备，核心包含Protein A或G亲和色谱步骤，提升抗体纯度与特异性。

三、研究应用方向

本产品靶向人Syndecan-1/CD138分子（该分子为细胞表面糖蛋白，参与细胞黏附、信号传导等过程），主要适配以下研究领域：

• 多发性骨髓瘤（MM）的发病机制、药物靶点验证研究；
• 其他CD138阳性实体瘤（如部分肺癌、乳腺癌等）的基础与转化研究。

四、科研应用类型

本抗体经验证可用于以下实验场景：

• ELISA：人源样本中CD138抗原的定量/定性检测；
• FACS：CD138阳性细胞的分选、表型分析；
• Functional assay：CD138分子介导的细胞功能（如增殖、迁移）研究；
• Research in vivo：动物模型中CD138相关生物学过程的体内研究（需符合伦理规范）。

五、免疫原与来源

• 来源宿主：Chimeric（嵌合型）；
• 免疫原信息：请参考产品附带的详细说明书。

六、反应性范围

本抗体仅针对人源（Human）样本具有特异性反应性，未验证其他物种交叉反应性。

七、储存与稳定性

为保障抗体活性，需遵循以下储存规范：

• 短期使用（1-2周）：4°C避光保存；
• 中短期储存（最长12个月）：-20°C避光保存；
• 长期储存：-80°C避光保存；
• 关键注意事项：全程避免反复冻融，以防抗体结构破坏导致活性下降。

注意：以上信息可能随着产品优化升级等因素产生变动，具体信息请咨询亚科因公司。

Product Core Information Overview

This product is the BioSIM anti-Human Syndecan-1/CD138 Antibody (Indatuximab Biosimilar) supplied by InvivoCrown, belonging to the category of biosimilars, designed specifically for research scenarios, with clear target specificity and application compatibility.

1. Basic Attributes

• English Full Name: BioSIM anti-Human Syndecan-1/CD138 Antibody (Indatuximab Biosimilar), Research Grade
• Chinese Full Name: BioSIM anti-Human Syndecan-1/CD138 Antibody (Indatuximab Biosimilar), Biosimilar, Research Use
• Supplier: InvivoCrown
• Product Catalog Number: SIM0234-1mg
• Single Unit Specification: 1mg

2. Production Process and Background

This antibody is a biosimilar of Indatuximab, and its production process adheres to strict quality control standards:

• Produced entirely in animal-component-free facilities to avoid the risk of introducing animal-derived contaminants;
• Only using protein-free in vitro cell culture technology to ensure production consistency between batches;
• Prepared through a multi-step purification process, with a core step of Protein A or G affinity chromatography to improve antibody purity and specificity.

3. Research Application Directions

This product targets the human Syndecan-1/CD138 molecule (a cell surface glycoprotein involved in processes such as cell adhesion and signal transduction), and is mainly suitable for the following research areas:

• Pathogenesis of multiple myeloma (MM) and drug target validation research;
• Basic and translational research on other CD138-positive solid tumors (such as some lung cancer, breast cancer, etc.).

4. Types of Scientific Research Applications

This antibody has been validated for use in the following experimental scenarios:

• ELISA: Quantitative/qualitative detection of CD138 antigen in human samples;
• FACS: Sorting and phenotypic analysis of CD138-positive cells;
• Functional assay: Research on CD138 molecule-mediated cellular functions (such as proliferation, migration);
• Research in vivo: In vivo studies of CD138-related biological processes in animal models (must comply with ethical guidelines).

5. Immunogen and Source

• Source Host: Chimeric;
• Immunogen Information: Please refer to the detailed manual accompanying the product.

6. Reactivity Range

This antibody only has specific reactivity against human samples; cross-reactivity with other species has not been verified.

7. Storage and Stability

To ensure antibody activity, the following storage specifications must be followed:

• Short-term use (1-2 weeks): Store at 4°C protected from light;
• Medium-short term storage (up to 12 months): Store at -20°C protected from light;
• Long-term storage: Store at -80°C protected from light;
• Key Notes: Avoid repeated freeze-thaw cycles throughout the process to prevent antibody structure damage and subsequent activity reduction.

Note: The above information may change due to factors such as product optimization and upgrading. For specific information, please consult Yakeyin Company.